IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A **substantially purified** chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinaceous or peptidyl tumoricidal agent, wherein said agent inhibits proliferation or reduces viability of tumor cells.

2. (Original) The chimeric protein of claim 1, wherein the tumoricidal agent induces apoptosis.

3. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand, or a biologically active fragment thereof, stimulates the proliferation of hematopoietic stem or progenitor cells.

4. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand, or a biologically active fragment thereof, stimulates the proliferation of cells selected from the group consisting of myeloid precursor cells, monocytic cells, macrophages, B-cells, dendritic cells and NK cells.

5. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand, or a biologically active fragment thereof, is a mammalian Flt3-ligand.

6. (Currently amended) The chimeric protein of claim **[[1]] 5**, wherein the mammalian Flt3 ligand, or a biologically active fragment thereof, is a human Flt3 ligand.

7. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand, or a biologically active fragment thereof, is a soluble Flt3 ligand.

8. (Previously presented) The chimeric protein of claim 1, wherein the Flt3 ligand comprises at least 100 amino acid residues and the Flt3 ligand has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:2, in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:2, and the Flt3 ligand substantially retains its biological activity.

9. (Previously presented) The chimeric protein of claim 1, wherein the Flt3 ligand binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:2 and the Flt3 ligand substantially retains its biological activity.

10. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand comprises the amino acid sequence set forth in SEQ ID NO:2.

11. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand comprises an amino acid sequence that is at least 80% identical to amino acids 28 to 128 of SEQ ID NO:2.

12. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand comprises amino acids 28 to 128 of SEQ ID NO:2.

13. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand comprises an amino acid sequence selected from the group consisting of amino acid residues 28-160 of SEQ ID NO:2, and amino acid residues 28-182 of SEQ ID NO:2.

14. (Original) The chimeric protein of claim 1, wherein the tumoricidal agent is an antibody.

15. (Original) The chimeric protein of claim 14, wherein the antibody is selected from the group consisting of an intact antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv

fragment, a diabody, a single-chain antibody and a multi-specific antibody formed from antibody fragments.

16. (Previously presented) The chimeric protein of claim 14, wherein the antibody is selected from the group consisting of an anti-p230 antibody, an anti-CD20 antibody, an anti-Her2 antibody, an anti-Her3 antibody, an anti-Her4 antibody, an anti-EGFR antibody or a biologically active fragment thereof.

17. (Original) The chimeric protein of claim 14, wherein the antibody is a human or humanized antibody.

18. (Withdrawn) The chimeric protein of claim 1, wherein the tumoricidal agent is selected from the group consisting of Fas ligand, TNF, TRAIL, or a biologically active extracellular domain thereof.

19. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand is located at the N-terminus of the chimeric protein.

20. (Original) The chimeric protein of claim 1, wherein the Flt3 ligand is located at the C-terminus of the chimeric protein.

21. (Currently amended) The chimeric protein of claim 1, wherein the Flt3 ligand and the ~~targeting~~ **tumoricidal** agent **[[is]]** **are** separated by a linking peptide.

22. (Currently amended) The chimeric protein of claim 21, wherein the linking peptide is ~~(Gly4Ser)3~~ **$(Gly_4Ser)_3$, SEQ ID NO:6**.

23. (Currently amended) The chimeric protein of claim 1, which comprises the amino acid sequence set forth in ~~SEQ ID NO:24, SEQ ID NO:26,~~ SEQ ID NO:28, ~~SEQ ID NO:30, SEQ ID NO:32,~~ SEQ ID NO:34, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.

24-34. (Cancelled)

35. (Previously presented) A pharmaceutical composition comprising an effective amount of a chimeric protein of claim 1 and a pharmaceutically acceptable carrier or excipient.

36. (Currently amended) A kit **for treating neoplasm in a mammal,** comprising an effective amount of a chimeric protein of claim 1 and an instruction means for administering said chimeric protein.

37-39. Cancelled

40. (Withdrawn) A combination, which combination comprises:

a) an effective amount of a chimeric protein of claim 1; and

b) an effective amount of an anti-neoplasm agent.

41. (Withdrawn) The combination of claim 40, wherein the anti-neoplasm agent is an agent that treats melanoma, breast cancer or hepatocellular carcinoma.

42-46. (Cancelled)

47. (Withdrawn) A vaccine comprising an effective amount of a chimeric protein of claim 1 and an immune response potentiator.

48-49. (Cancelled)

50. (Previously presented) A chimeric protein comprising a Flt3 ligand, or a biologically active fragment thereof, and an antibody which inhibits proliferation or reduces viability of tumor cells.

51. (Previously presented) The chimeric protein of claim 50, wherein the antibody is selected from the group consisting of an intact antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, a single-chain antibody and a multi-specific antibody formed from antibody fragments.

52. (Previously presented) The chimeric protein of claim 50, wherein the antibody is selected from the group consisting of an anti-p230 antibody, an anti-CD20 antibody, an anti-Her2 antibody, an anti-Her3 antibody, an anti-Her4 antibody, an anti-EGFR antibody or a biologically active fragment thereof.

53. (Previously presented) The chimeric protein of claim 50, wherein the antibody is a human or humanized antibody.

54. (Previously presented) The chimeric protein of claim 50, wherein the Flt3 ligand is located at the N-terminus of the chimeric protein.

55. (Previously presented) The chimeric protein of claim 50, wherein the Flt3 ligand is located at the C-terminus of the chimeric protein.

56. (Currently amended) The chimeric protein of claim 50, wherein the Flt3 ligand and the antibody **[[is]]** **<u>are</u>** separated by a linking peptide.

57. (Currently amended) The chimeric protein of claim **[[57]]** **56**, wherein the linking peptide is ~~**(Gly4Ser)3**~~ **$(Gly_4Ser)_3$, SEQ ID NO:6**.

58. (New) The chimeric protein of claim 10, wherein the tumoricidal agent is an antibody.

59. (New) The chimeric protein of claim 10, wherein the antibody is selected from the group consisting of an intact antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, a single-chain antibody and a multi-specific antibody formed from antibody fragments.

60. (New) The chimeric protein of claim 10, wherein the antibody is selected from the group consisting of an anti-p230 antibody, an anti-CD20 antibody, an anti-Her2 antibody, an anti-Her3 antibody, an anti-Her4 antibody, an anti-EGFR antibody or a biologically active fragment thereof.

61. (New) The chimeric protein of claim 10, wherein the tumoricidal agent is selected from the group consisting of Fas ligand, TNF, TRAIL, or a biologically active extracellular domain thereof.

62. (New) The chimeric protein of claim 10, wherein the Flt3 ligand and the tumoricidal agent are separated by a linking peptide.

63. (New) The chimeric protein of claim 13, wherein the tumoricidal agent is an antibody.

64. (New) The chimeric protein of claim 13, wherein the antibody is selected from the group consisting of an intact antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, a single-chain antibody and a multi-specific antibody formed from antibody fragments.

65. (New) The chimeric protein of claim 13, wherein the antibody is selected from the group consisting of an anti-p230 antibody, an anti-CD20 antibody, an anti-Her2 antibody, an anti-Her3 antibody, an anti-Her4 antibody, an anti-EGFR antibody or a biologically active fragment thereof.

66. (New) The chimeric protein of claim 13, wherein the tumoricidal agent is selected from the group consisting of Fas ligand, TNF, TRAIL, or a biologically active extracellular domain thereof.

67. (New) The chimeric protein of claim 13, wherein the Flt3 ligand and the tumoricidal agent are separated by a linking peptide.